{"ticker": {"uuid": "cc0e5b86-229f-4403-9bff-86fc2ec23f6c", "symbol": "VSTM", "name": "Verastem Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)", "summary": "RBC Capital has reaffirmed its Outperform rating for Verastem Inc. (VSTM) and adjusted its price target from $15 to $14, still implying over 211% upside potential. This adjustment follows RBC's Q2 biotech sector preview, which noted strong momentum driven by encouraging data and ", "url": "https://ca.finance.yahoo.com/news/rbc-capital-reaffirms-outperform-rating-154312539.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-15T17:18:45", "published_display": "15 Jul 2026 17:18", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (VSTM) Edition", "summary": "This article analyzes Verastem Inc. (VSTM), highlighting a near- and mid-term strong sentiment with a weak long-term outlook and a mid-channel oscillation pattern. It presents three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entr", "url": "https://news.stocktradersdaily.com/news_release/34/Trading_the_Move,_Not_the_Narrative:_VSTM_Edition_071326090402_1783991042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T21:04:00", "published_display": "13 Jul 2026 21:04", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPU09nRktIR3VQWmVIZXh4OWJjbG5Hbl96UVBTY1BmVWFPRi1xeE55VDRtZWZMQXNlQThNcTlaamM1b1JKMzdaNHU3SzBsY2QwQlZacU00SFNQTU5yVk5td25WVnhwMkJ6cngyWkhjSTFMT2FDSlE2MHdkV0JtM2JaVllQbDlIMl9RdHUzRDNqZndMWmc?oc=5", "source_name": "Market source", "published_at": "2026-07-10T09:45:00+00:00", "published_display": "10 Jul 2026 09:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polar Capital group files 13G/A reporting 3.7M shares in Verastem (VSTM)", "summary": "Polar Capital group has filed a 13G/A, disclosing beneficial ownership of 3.7 million shares in Verastem, Inc. (VSTM), which represents a 4.80% stake in the company. The filing indicates sole voting and dispositive power over these shares for the group, consisting of Polar Capita", "url": "https://www.stocktitan.net/sec-filings/VSTM/schedule-13g-a-verastem-inc-amended-passive-investment-disclosure-2fde11625179.html", "source_name": "Stock Titan", "published_at": "2026-07-08T13:39:07", "published_display": "08 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14", "summary": "RBC Capital has reaffirmed its Buy rating on Verastem (VSTM.US) but has reduced its target price to $14. This adjustment suggests a continued positive outlook on the company despite the lower price target, indicating potential confidence in its long-term prospects.", "url": "https://www.moomoo.com/news/post/72587144/rbc-capital-maintains-verastem-vstmus-with-buy-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-07-07T22:04:23", "published_display": "07 Jul 2026 22:04", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Inc outlines oncology focus as investors weigh long-term prospects", "summary": "Verastem Inc, an oncology-focused biotech company, is developing targeted cancer therapies, and its long-term prospects are being assessed by investors. The company operates in a high-risk, high-potential segment of the healthcare sector, where clinical data and regulatory decisi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/verastem-inc-outlines-oncology-focus-as-investors-weigh-long-term/69717308", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T20:10:15", "published_display": "07 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating", "summary": "RBC Capital has adjusted its price target for Verastem (VSTM) to $14, down from $15, while reaffirming an Outperform rating on the stock. Verastem is a late-stage biopharmaceutical company focused on developing therapies for RAS/MAPK pathway-driven cancers, with product candidate", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-verastem-price-target-to-14-from-15-maintains-outperform-rating-ce7f5ed8d981f52d", "source_name": "marketscreener.com", "published_at": "2026-07-07T12:10:15", "published_display": "07 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What RBC Capital Has to Say About Verastem (VSTM)", "summary": "RBC Capital has reiterated an Outperform rating on Verastem (VSTM) with a $15 price target, driven by the potential of the company's G12D inhibitor drug program targeting specific genetic mutations in cancers. While acknowledging risks and some safety profile improvement potentia", "url": "https://www.insidermonkey.com/blog/heres-what-rbc-capital-has-to-say-about-verastem-vstm-1794178/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:10:55", "published_display": "03 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Verastem Oncology announced the grant of 399,750 restricted stock units and 91,000 stock options to new employees. These grants were made under the Nasdaq inducement grant exception as an incentive for accepting employment with the company. The stock options have an exercise pric", "url": "https://sg.finance.yahoo.com/news/verastem-oncology-announces-inducement-grants-203000239.html", "source_name": "Market source", "published_at": "2026-07-03T08:39:45", "published_display": "03 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VSTM Maintained by BTIG -- Price Target Unchanged at $18.00", "summary": "BTIG has maintained a \"Buy\" rating on Verastem (VSTM) with an unchanged price target of $18.00, signaling confidence despite the company's low GF Score\u2122 of 11/100, which indicates significant financial and profitability challenges. While analysts see potential upside from the cur", "url": "https://www.gurufocus.com/news/8943500/vstm-maintained-by-btig-price-target-unchanged-at-1800", "source_name": "GuruFocus", "published_at": "2026-07-02T18:52:05", "published_display": "02 Jul 2026 18:52", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem awards stock grants to 31 new employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUVhMaUk0eHlpaUFlMlFRUk43MFlMQzB0ejFKa0NucHhLdjdXbldpUXpNY1BReHFFajlCVUhMVXQ5bnhoTUpoWWJBVld1MWRwOFZCbEJBc0xZQWFnWURpOERzVk01a3JzRGV1Nm1ESzExSDNHbWF6el9DdnJTcEwwMmxMX203WDZLZ3ItT3p4aC1uWXluaTE0aTdiTy0wN296eTBkSm8wZGNyUWU1TElrVlhWc2dFRlZ1UVNTQ1dn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Verastem, Inc. \u2013 NASDAQ:VSTM", "summary": "This article provides an analysis of the enterprise value to EBIT forward for Verastem, Inc. (NASDAQ:VSTM), indicating financial metrics from sources like ICE Data Services and FactSet. The content is presented within the TradingView platform, focusing on the company's financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T19:42:05", "published_display": "01 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial", "summary": "Verastem Inc. (NASDAQ: VSTM) has released encouraging initial findings from its TARGET-D 101 Phase 1/2 trial for VS-7375, an experimental oral KRAS G12D inhibitor. The drug demonstrated positive clinical activity and a good safety profile across various dosage levels and tumor ty", "url": "https://www.insidermonkey.com/blog/verastem-vstm-shares-encouraging-results-from-vs-7375-phase-1-2-trial-1792174/", "source_name": "Insider Monkey", "published_at": "2026-06-30T16:09:46", "published_display": "30 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. Actuals & Estimates (SWB:2VSA)", "summary": "This article provides an overview of Verastem, Inc. (SWB:2VSA) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It also covers analyst price targets, historical stock performance, upcoming earnings dates, and key financial me", "url": "https://www.tradingview.com/symbols/SWB-2VSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:12", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM)", "summary": "This article provides an overview of Verastem, Inc. (NASDAQ:VSTM) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's financial actuals and estimates for the income statement, balance sheet, and cash flow,", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:24", "published_display": "26 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Verastem, Inc. \u2013 NASDAQ:VSTM", "summary": "This article displays financial data for Verastem, Inc. (NASDAQ: VSTM), specifically its price-to-earnings forward metric. The content appears to be a stub or a placeholder from TradingView, indicating where this financial information would typically be presented, though no actua", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:24", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VSTM Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Verastem, Inc. (VSTM) stock, including analyst price targets, current stock performance, and key financial metrics. It highlights a max price estimate of $18.00 and a min estimate of $8.00 from analysts, alongside details on its current tradin", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:51", "published_display": "26 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem CFO Daniel Calkins sells $17,089 in company stock", "summary": "Verastem CFO Daniel Calkins sold $17,089 worth of company stock on June 22, 2026, to cover tax withholding requirements related to restricted stock unit vesting. Following the sale of 4,089 shares, Calkins still directly owns 117,238 shares of VSTM. This transaction comes as the ", "url": "https://www.investing.com/news/insider-trading-news/verastem-cfo-daniel-calkins-sells-17089-in-company-stock-93CH-4759106", "source_name": "Investing.com", "published_at": "2026-06-25T22:04:23", "published_display": "25 Jun 2026 22:04", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Verastem, Inc. \u2013 NASDAQ:VSTM", "summary": "This article provides financial information for Verastem, Inc. (NASDAQ: VSTM), specifically focusing on its forward price-to-book ratio. It appears to be a financial data snippet from a platform like TradingView, offering a snapshot of a particular metric for the company. The con", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:41:16", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) insider sale notice: 21,492 shares reported for resale", "summary": "Verastem Inc. has filed a Form 144 notice for the proposed resale of 21,492 shares of common stock by insider Robert Gagnon. These shares originated from vested Restricted Stock Units dated December 15, 2021. The filing also indicates that Gagnon sold 20,103 shares in the past th", "url": "https://www.stocktitan.net/sec-filings/VSTM/144-verastem-inc-sec-filing-4c001dcea49d.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:41:16", "published_display": "25 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. Actuals & Estimates (GETTEX:2VSA)", "summary": "This article provides an overview of Verastem, Inc. (2VSA) stock performance, financial data, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. Additionally, it includes answers t", "url": "https://www.tradingview.com/symbols/GETTEX-2VSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:16", "published_display": "25 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Verastem, Inc. \u2013 GETTEX:2VSA", "summary": "This page from TradingView displays financial information for Verastem, Inc. (2VSA on GETTEX), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates the market is closed for this stock and no trades have occurred for the displayed period.", "url": "https://www.tradingview.com/symbols/GETTEX-2VSA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:43", "published_display": "25 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Verastem, Inc. (VSTM)\u2019s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?", "summary": "Verastem, Inc. (VSTM) is exploring KRAS-targeted combination therapies for pancreatic cancer. Recent updates from the RAMP 205 Phase 1b/2a study demonstrated safety and efficacy findings for a combination therapy in metastatic pancreatic ductal adenocarcinoma, while the TARGET-D ", "url": "https://www.insidermonkey.com/blog/is-verastem-inc-vstms-kras-targeted-combination-therapy-a-breakthrough-for-pancreatic-cancer-1788984/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-25T12:40:43", "published_display": "25 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Inc (VSTM) CEO Dan Paterson Sells 20,871 Shares", "summary": "Verastem Inc's CEO, Dan Paterson, sold 20,871 shares on June 22, 2026, reducing his holdings to 591,242 shares. This sale is part of a trend over the last year where insiders have only sold shares, with no purchases. Verastem Inc is a biopharmaceutical company focused on cancer t", "url": "https://www.gurufocus.com/news/8930803/verastem-inc-vstm-ceo-dan-paterson-sells-20871-shares?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-25T06:40:43", "published_display": "25 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) CEO sells 20,871 shares to cover RSU tax withholding", "summary": "Verastem, Inc. President and CEO Dan Paterson sold 20,871 shares of common stock at $4.18 per share. This sale was conducted to cover statutory withholding taxes related to the vesting of restricted stock units, not for discretionary trading. Following the transaction, Paterson d", "url": "https://www.stocktitan.net/sec-filings/VSTM/form-4-verastem-inc-insider-trading-activity-1ba344613da7.html", "source_name": "Stock Titan", "published_at": "2026-06-25T04:04:07", "published_display": "25 Jun 2026 04:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Verastem Inc For: 24 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Verastem Inc., related to activities on June 24th. The article is very brief, providing only the filing information and a stock price change for VSTM. It includes various market data and popular articles as typical pl", "url": "https://za.investing.com/news/stock-market-news/form-4-verastem-inc-for-24-june-93CH-4342790", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T02:40:44", "published_display": "25 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (NASDAQ: VSTM) CFO sells 4,089 shares to cover RSU taxes", "summary": "Verastem, Inc.'s CFO, Daniel Calkins, sold 4,089 shares of common stock on June 22, 2026, in two tranches at $4.13 and $4.18 per share. These sales were not discretionary but were made to satisfy statutory tax withholding requirements related to the vesting of restricted stock un", "url": "https://www.stocktitan.net/sec-filings/VSTM/form-4-verastem-inc-insider-trading-activity-b0d49f253997.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:11:07", "published_display": "24 Jun 2026 21:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verastem-apos-vs-7375-reiterates-151318601.html", "source_name": "MT Newswires", "published_at": "2026-06-24T15:13:18+00:00", "published_display": "24 Jun 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital reiterates Verastem stock rating on G12D inhibitor potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNM0h4MTdRRkNYZEQtemZDTEFMb3Zac0Q1TmhCb0NmMWNBTnpkVEN3bFhOMWwwMHpKaUhzSHFkZjc2UjRUY1FoOGp6YmpsR3psVEdJYlZkNlk5THZYb3J3bDJ4a1BmMkFPQlk2Z0tRQjJzbjBBVTVSTjVJZl85aVMzU0lxZ0F0bFA5dnJzQkREUFV4RXhJc0JCWjdTcHdYRmVzbVBmZmtPUHpjMFpGQ3BmTVpoenNxVE8zajFLbVByeDB4MW1rYVM5RDlBZEs?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Verastem stock rating on drug trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNS0pxeEdVcy1vVjdoaUpCY05rN0pJSXhfYXVKMDRoMS16MnVpVFB2aFFmcDJWQ2sxTU15MTladmNFZnhmd0dudk5FVkJDQ0toMEVNQ1FXWmpNV0RCWlhHcW1iYmxPNWZBNnIwaTk3ZEpzU1IwNW1TdnpkWVY0eHFkYWlHcm96VEkxREUzeUpmajJwaGdFbHc5bGprNmh4QllXcGZXajdyRkdpeFlfQ3Bqcmo3OUhmdWo3Ulc2QTV6dERkMFE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verastem-says-vs-7375-trial-204406965.html", "source_name": "MT Newswires", "published_at": "2026-06-23T20:44:06+00:00", "published_display": "23 Jun 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem posts VS-7375 data, reports anti-tumor activity at 400\u2013900 mg QD and 93% CA19-9 drops in mPDAC", "summary": "Verastem reported positive preliminary data for its drug VS-7375, showing anti-tumor activity at doses of 400\u2013900 mg once daily and significant biomarker responses in metastatic pancreatic ductal adenocarcinoma (mPDAC). Key findings include ongoing dose escalation, anti-tumor act", "url": "https://www.tradingview.com/news/tradingview:76de15f6e44cd:0-verastem-posts-vs-7375-data-reports-anti-tumor-activity-at-400-900-mg-qd-and-93-ca19-9-drops-in-mpdac/", "source_name": "TradingView", "published_at": "2026-06-23T20:09:27", "published_display": "23 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem says VS-7375 hit pancreatic, colon and lung tumors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMHd4QU5HNFpld284N25OSTNtT3hJcEhvOHBqSi1WMzVENHkxcDROVUtTYi1yN3NOYl9ickRwdW44STU2aVdsdDZpSkRMZloxQXpjS0VpSm50bVc0TkJQWHdhbEhyVnpESi1wNHl4UVNodEIzLUh0bmJZRUl1YzNER1Izc2Y3QUhScEsweWVobHhKa0dmV0R1dWg5YUxEelJocjZ6aThMVkhRemFhU3A4N0pEQjJoMG12dEsxdnl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem stock falls despite early cancer drug trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMDFzNHlCX3R4bXBHeTA4aHppZkE5T2RhbTAyVkZlczlZSmlROUp3dWh3U29NazJmX1JZUWh3WTN4ZzdIQ1RmUXcycGpjaTZGMmJFdWNPRXBadFdkRUVTT2RudDdhSUJFM192cWRmZVZvZTBwLTY1NzJLak9KRVVwSkNYeXl5N3k5R05oMG9oRzk0NlFlS1N2VDZ2Ym9faFh6T1lMWmlHb2ZCMzRpUTMzQ0t5NkJhdnYxM1pn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (NASDAQ: VSTM) insider sale notice \u2014 20,871 shares proposed", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOUFBQM094M3ZVcEh3WkJXTHFxSTZzT2JTNTFFVVZrR2pTTEw4NnZrdm1hRHdsc0hPX2xfQ2oxR3ZEV0JSTVFqNWxfRzY2U28zc3dDR3ZoelNjSlAxZ1EzVm54V1lXSWZzQTgtV1BJeUFSTTJzaVdiZUoxRTUySTU3ZktDTXRyTHY2bGJOQk1FUXdmTnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung", "summary": "", "url": "https://news.google.com/rss/articles/CBMisANBVV95cUxONmFJeHZXdnBraloxUXY4QlJyRS1LQndTalRaUVpvcWdlWjFkN1hxNzNpYnRJM3NHaW0yWDJ2RGw3Rm14aTRvTzdMb2NseWlPd2ZUNUFOZjZoZm9kYmdGMXE2YTYxUG5IMlJPQjl4TFR1ZS1FVHEzY2xtVkx4WXJSekpNZTNzcUFKOFdNa2czSjl0OW02dkhhdHhFcHNxMmVscF8zTmN1SE1wMWN1MDRhYXJ5Z0ljelM4djlocEdpWVVPNE1ibl9jSVlGVnljbDRWcTFTajZrajlaV2JJOGdXdDM5anBzbGRoZm0tb0RTY255YzJkVk9hdHpNNnhKc3BSVzRQd2Q4MGhwdVpFV2xSaTlEVG91WWVqSS1ZTnBhOFBzYVlNZVpWdHZ4b1dncUx4dHVVU0xLZDZYSFRobWxNZGhKcEx0Nlo4TG5iVkYzek5hbWdsbVJ4YUpnTEpWUEYzYUZ1aXNFRG1hT2hLTzJUN2Y4ekNzZ2FUbjB2czlhaFRQUmd6YlpicGpOb1E1NkVWQ2FBU252U2RqaVhibW52QWhWWTQwSjNNWnFOVFFoQ2g?oc=5", "source_name": "Business Wire", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Verastem, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNTk45QzJvdmtiRHByXzd0VTNJMXFlN3FCeE1FSVZmaFcxY2RuNm5KNG9wcjBPTW9uNWgzQmZxb3dERWUyUzdYZmszVm9XT0RVNTAtSFc4M1RxSjVlV2NjR01XbHA2RGVXYWRWZ1Bac2pzR2RUNjlOYlJQQ1JkUjF4bWU5emp5ZllMYk00TmxHbW9QY3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNQVFveUFVbEFta3pzVFdmS3dXajdZZ1ppYndTaDl2TS1pVFViOUw0dE1jRl9KWEZqX3FiT0dLMUhBTWJPdndRRDJJOFdVSURGcXhpWDB0X2pYV0t1OTZZUm5nVDR2Vk94cVBQbEppTzhuZnhBdnJ5S3B2dVltUlU2NV93QXQ3V3FiT2VBRU5EZy1PaWM?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts Think", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNSW5BdlpVVXd1cDF4WGVkYTZzVjF6MmxHNWRtcXktMldRdHhYb3JzVVMxMTFDLVZUZ1lKRk1sM0RoRlRxM00xV2FrMEhKNUl6czl5RXk0eFZwaFljUURzbHNjaktJWXN0TU1kaVJmV0FIMExQWWpqbXBkaWUzU0VpT1BreHFfeVFLQXJWUzFFT19aQVpiSmpQTV9B?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Verastem (VSTM) Q4 Revenue Reaches US$17.5 Million Yet Heavy Losses Reinforce Bearish Views", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxPU2ZsN0o4bVI5dnd3b0V0V01RRDd3LURtMEpiTWNtVzhTcXRTUTVmTGwta0RVQm1yajk3cHk0Z24xQ056UDVoSXpzVTZlT0ZfOG9sb1llVnpoQmt2TFVaLWo1YTRwVUU5eGc2SU42eGMxR0NWU0dfanBlZ1QtRUdEczFxNkdJSl8xQ2U5YnVsa19vMm1tdjNpNzdOWi0tY2FtbFAxODZDM29aeWFBalF5Q3c5X1hEaWEzTmFtQUJYZUxhVWZKSXZFTUtMQ2JrYVpyckVhUmFVZE53MWx3UWt3LTNxeUxNN2d2dm1hQi1MZw?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQT2V0TV94Z091d1U4eHhTMS1VNjNQUVVRY2tjeEF4QWc3Uzl4Zy1sSGlxdlRUZTBjWFZWRVVmSmg2VExpX0k0Wm1fQndLR1preW5aSmRfNzJpcy11RUJObm5QRTdkb2lLeVJyaTlTUXdWRVRMX2tMRWMxa1B4anlvc1Z0UGlaTXE0UlAtUk1LTlk4U2R1Z3Y0OVFn?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPWDlaVlFMX2V1WVFsU2FZYmQwVExESnBaR1U4SUNPZGJ3ZFlLdHNIY0hYWkFzcmdVZXlxdldtbk14SDZzbHNrX3AzT3hHcnd2eXRFdTlXOC1STFlNTHpIck1HM0xJMFVUV3pOM1FfbWROdDF5Tk53WXZJUV9zT3VDb1pSd0hGeE9ZaXBqZTVianZDRzlXY1g1MEtQYmFJQk4zcFVtVUo0VWE4MWVWd19kUHFxakZiWm9IXzlZTDNmWTZFOTBIaXRz?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Verastem (VSTM) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb0I0VkFIVm5TWnpsY1BLRUtOMTltU2NoaGRoM05WZGtSLVpLMGhjMUJickR3UERNeHBnQTJjdWUwcHhVYW15dlZNaldaRzRxU2VPOE9yZENVQVZMbjl2d1JBWloyVHdrOTR5SzFsMi1mcmI3b3pNSGM2eHZuSld0Zg?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Verastem Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-26T08:00:00+00:00", "published_display": "26 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)", "summary": "RBC Capital has reaffirmed its Outperform rating for Verastem Inc. (VSTM) and adjusted its price target from $15 to $14, still implying over 211% upside potential. This adjustment follows RBC's Q2 biotech sector preview, which noted strong momentum driven by encouraging data and ", "url": "https://ca.finance.yahoo.com/news/rbc-capital-reaffirms-outperform-rating-154312539.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-15T17:18:45", "published_display": "15 Jul 2026 17:18", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (VSTM) Edition", "summary": "This article analyzes Verastem Inc. (VSTM), highlighting a near- and mid-term strong sentiment with a weak long-term outlook and a mid-channel oscillation pattern. It presents three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entr", "url": "https://news.stocktradersdaily.com/news_release/34/Trading_the_Move,_Not_the_Narrative:_VSTM_Edition_071326090402_1783991042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T21:04:00", "published_display": "13 Jul 2026 21:04", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPU09nRktIR3VQWmVIZXh4OWJjbG5Hbl96UVBTY1BmVWFPRi1xeE55VDRtZWZMQXNlQThNcTlaamM1b1JKMzdaNHU3SzBsY2QwQlZacU00SFNQTU5yVk5td25WVnhwMkJ6cngyWkhjSTFMT2FDSlE2MHdkV0JtM2JaVllQbDlIMl9RdHUzRDNqZndMWmc?oc=5", "source_name": "Market source", "published_at": "2026-07-10T09:45:00+00:00", "published_display": "10 Jul 2026 09:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polar Capital group files 13G/A reporting 3.7M shares in Verastem (VSTM)", "summary": "Polar Capital group has filed a 13G/A, disclosing beneficial ownership of 3.7 million shares in Verastem, Inc. (VSTM), which represents a 4.80% stake in the company. The filing indicates sole voting and dispositive power over these shares for the group, consisting of Polar Capita", "url": "https://www.stocktitan.net/sec-filings/VSTM/schedule-13g-a-verastem-inc-amended-passive-investment-disclosure-2fde11625179.html", "source_name": "Stock Titan", "published_at": "2026-07-08T13:39:07", "published_display": "08 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14", "summary": "RBC Capital has reaffirmed its Buy rating on Verastem (VSTM.US) but has reduced its target price to $14. This adjustment suggests a continued positive outlook on the company despite the lower price target, indicating potential confidence in its long-term prospects.", "url": "https://www.moomoo.com/news/post/72587144/rbc-capital-maintains-verastem-vstmus-with-buy-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-07-07T22:04:23", "published_display": "07 Jul 2026 22:04", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Inc outlines oncology focus as investors weigh long-term prospects", "summary": "Verastem Inc, an oncology-focused biotech company, is developing targeted cancer therapies, and its long-term prospects are being assessed by investors. The company operates in a high-risk, high-potential segment of the healthcare sector, where clinical data and regulatory decisi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/verastem-inc-outlines-oncology-focus-as-investors-weigh-long-term/69717308", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T20:10:15", "published_display": "07 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating", "summary": "RBC Capital has adjusted its price target for Verastem (VSTM) to $14, down from $15, while reaffirming an Outperform rating on the stock. Verastem is a late-stage biopharmaceutical company focused on developing therapies for RAS/MAPK pathway-driven cancers, with product candidate", "url": "https://www.marketscreener.com/news/rbc-capital-adjusts-verastem-price-target-to-14-from-15-maintains-outperform-rating-ce7f5ed8d981f52d", "source_name": "marketscreener.com", "published_at": "2026-07-07T12:10:15", "published_display": "07 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What RBC Capital Has to Say About Verastem (VSTM)", "summary": "RBC Capital has reiterated an Outperform rating on Verastem (VSTM) with a $15 price target, driven by the potential of the company's G12D inhibitor drug program targeting specific genetic mutations in cancers. While acknowledging risks and some safety profile improvement potentia", "url": "https://www.insidermonkey.com/blog/heres-what-rbc-capital-has-to-say-about-verastem-vstm-1794178/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:10:55", "published_display": "03 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Verastem Oncology announced the grant of 399,750 restricted stock units and 91,000 stock options to new employees. These grants were made under the Nasdaq inducement grant exception as an incentive for accepting employment with the company. The stock options have an exercise pric", "url": "https://sg.finance.yahoo.com/news/verastem-oncology-announces-inducement-grants-203000239.html", "source_name": "Market source", "published_at": "2026-07-03T08:39:45", "published_display": "03 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VSTM Maintained by BTIG -- Price Target Unchanged at $18.00", "summary": "BTIG has maintained a \"Buy\" rating on Verastem (VSTM) with an unchanged price target of $18.00, signaling confidence despite the company's low GF Score\u2122 of 11/100, which indicates significant financial and profitability challenges. While analysts see potential upside from the cur", "url": "https://www.gurufocus.com/news/8943500/vstm-maintained-by-btig-price-target-unchanged-at-1800", "source_name": "GuruFocus", "published_at": "2026-07-02T18:52:05", "published_display": "02 Jul 2026 18:52", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem awards stock grants to 31 new employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQUVhMaUk0eHlpaUFlMlFRUk43MFlMQzB0ejFKa0NucHhLdjdXbldpUXpNY1BReHFFajlCVUhMVXQ5bnhoTUpoWWJBVld1MWRwOFZCbEJBc0xZQWFnWURpOERzVk01a3JzRGV1Nm1ESzExSDNHbWF6el9DdnJTcEwwMmxMX203WDZLZ3ItT3p4aC1uWXluaTE0aTdiTy0wN296eTBkSm8wZGNyUWU1TElrVlhWc2dFRlZ1UVNTQ1dn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Verastem, Inc. \u2013 NASDAQ:VSTM", "summary": "This article provides an analysis of the enterprise value to EBIT forward for Verastem, Inc. (NASDAQ:VSTM), indicating financial metrics from sources like ICE Data Services and FactSet. The content is presented within the TradingView platform, focusing on the company's financial ", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T19:42:05", "published_display": "01 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial", "summary": "Verastem Inc. (NASDAQ: VSTM) has released encouraging initial findings from its TARGET-D 101 Phase 1/2 trial for VS-7375, an experimental oral KRAS G12D inhibitor. The drug demonstrated positive clinical activity and a good safety profile across various dosage levels and tumor ty", "url": "https://www.insidermonkey.com/blog/verastem-vstm-shares-encouraging-results-from-vs-7375-phase-1-2-trial-1792174/", "source_name": "Insider Monkey", "published_at": "2026-06-30T16:09:46", "published_display": "30 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. Actuals & Estimates (SWB:2VSA)", "summary": "This article provides an overview of Verastem, Inc. (SWB:2VSA) financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data. It also covers analyst price targets, historical stock performance, upcoming earnings dates, and key financial me", "url": "https://www.tradingview.com/symbols/SWB-2VSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T08:39:12", "published_display": "27 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM)", "summary": "This article provides an overview of Verastem, Inc. (NASDAQ:VSTM) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's financial actuals and estimates for the income statement, balance sheet, and cash flow,", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:24", "published_display": "26 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Verastem, Inc. \u2013 NASDAQ:VSTM", "summary": "This article displays financial data for Verastem, Inc. (NASDAQ: VSTM), specifically its price-to-earnings forward metric. The content appears to be a stub or a placeholder from TradingView, indicating where this financial information would typically be presented, though no actua", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:24", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VSTM Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Verastem, Inc. (VSTM) stock, including analyst price targets, current stock performance, and key financial metrics. It highlights a max price estimate of $18.00 and a min estimate of $8.00 from analysts, alongside details on its current tradin", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:51", "published_display": "26 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem CFO Daniel Calkins sells $17,089 in company stock", "summary": "Verastem CFO Daniel Calkins sold $17,089 worth of company stock on June 22, 2026, to cover tax withholding requirements related to restricted stock unit vesting. Following the sale of 4,089 shares, Calkins still directly owns 117,238 shares of VSTM. This transaction comes as the ", "url": "https://www.investing.com/news/insider-trading-news/verastem-cfo-daniel-calkins-sells-17089-in-company-stock-93CH-4759106", "source_name": "Investing.com", "published_at": "2026-06-25T22:04:23", "published_display": "25 Jun 2026 22:04", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Verastem, Inc. \u2013 NASDAQ:VSTM", "summary": "This article provides financial information for Verastem, Inc. (NASDAQ: VSTM), specifically focusing on its forward price-to-book ratio. It appears to be a financial data snippet from a platform like TradingView, offering a snapshot of a particular metric for the company. The con", "url": "https://www.tradingview.com/symbols/NASDAQ-VSTM/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:41:16", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) insider sale notice: 21,492 shares reported for resale", "summary": "Verastem Inc. has filed a Form 144 notice for the proposed resale of 21,492 shares of common stock by insider Robert Gagnon. These shares originated from vested Restricted Stock Units dated December 15, 2021. The filing also indicates that Gagnon sold 20,103 shares in the past th", "url": "https://www.stocktitan.net/sec-filings/VSTM/144-verastem-inc-sec-filing-4c001dcea49d.html", "source_name": "Stock Titan", "published_at": "2026-06-25T19:41:16", "published_display": "25 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. Actuals & Estimates (GETTEX:2VSA)", "summary": "This article provides an overview of Verastem, Inc. (2VSA) stock performance, financial data, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. Additionally, it includes answers t", "url": "https://www.tradingview.com/symbols/GETTEX-2VSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:16", "published_display": "25 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Verastem, Inc. \u2013 GETTEX:2VSA", "summary": "This page from TradingView displays financial information for Verastem, Inc. (2VSA on GETTEX), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates the market is closed for this stock and no trades have occurred for the displayed period.", "url": "https://www.tradingview.com/symbols/GETTEX-2VSA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:40:43", "published_display": "25 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Verastem, Inc. (VSTM)\u2019s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?", "summary": "Verastem, Inc. (VSTM) is exploring KRAS-targeted combination therapies for pancreatic cancer. Recent updates from the RAMP 205 Phase 1b/2a study demonstrated safety and efficacy findings for a combination therapy in metastatic pancreatic ductal adenocarcinoma, while the TARGET-D ", "url": "https://www.insidermonkey.com/blog/is-verastem-inc-vstms-kras-targeted-combination-therapy-a-breakthrough-for-pancreatic-cancer-1788984/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-25T12:40:43", "published_display": "25 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Inc (VSTM) CEO Dan Paterson Sells 20,871 Shares", "summary": "Verastem Inc's CEO, Dan Paterson, sold 20,871 shares on June 22, 2026, reducing his holdings to 591,242 shares. This sale is part of a trend over the last year where insiders have only sold shares, with no purchases. Verastem Inc is a biopharmaceutical company focused on cancer t", "url": "https://www.gurufocus.com/news/8930803/verastem-inc-vstm-ceo-dan-paterson-sells-20871-shares?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-25T06:40:43", "published_display": "25 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) CEO sells 20,871 shares to cover RSU tax withholding", "summary": "Verastem, Inc. President and CEO Dan Paterson sold 20,871 shares of common stock at $4.18 per share. This sale was conducted to cover statutory withholding taxes related to the vesting of restricted stock units, not for discretionary trading. Following the transaction, Paterson d", "url": "https://www.stocktitan.net/sec-filings/VSTM/form-4-verastem-inc-insider-trading-activity-1ba344613da7.html", "source_name": "Stock Titan", "published_at": "2026-06-25T04:04:07", "published_display": "25 Jun 2026 04:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Verastem Inc For: 24 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Verastem Inc., related to activities on June 24th. The article is very brief, providing only the filing information and a stock price change for VSTM. It includes various market data and popular articles as typical pl", "url": "https://za.investing.com/news/stock-market-news/form-4-verastem-inc-for-24-june-93CH-4342790", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T02:40:44", "published_display": "25 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (NASDAQ: VSTM) CFO sells 4,089 shares to cover RSU taxes", "summary": "Verastem, Inc.'s CFO, Daniel Calkins, sold 4,089 shares of common stock on June 22, 2026, in two tranches at $4.13 and $4.18 per share. These sales were not discretionary but were made to satisfy statutory tax withholding requirements related to the vesting of restricted stock un", "url": "https://www.stocktitan.net/sec-filings/VSTM/form-4-verastem-inc-insider-trading-activity-b0d49f253997.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:11:07", "published_display": "24 Jun 2026 21:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verastem-apos-vs-7375-reiterates-151318601.html", "source_name": "MT Newswires", "published_at": "2026-06-24T15:13:18+00:00", "published_display": "24 Jun 2026 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital reiterates Verastem stock rating on G12D inhibitor potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNM0h4MTdRRkNYZEQtemZDTEFMb3Zac0Q1TmhCb0NmMWNBTnpkVEN3bFhOMWwwMHpKaUhzSHFkZjc2UjRUY1FoOGp6YmpsR3psVEdJYlZkNlk5THZYb3J3bDJ4a1BmMkFPQlk2Z0tRQjJzbjBBVTVSTjVJZl85aVMzU0lxZ0F0bFA5dnJzQkREUFV4RXhJc0JCWjdTcHdYRmVzbVBmZmtPUHpjMFpGQ3BmTVpoenNxVE8zajFLbVByeDB4MW1rYVM5RDlBZEs?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Verastem stock rating on drug trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNS0pxeEdVcy1vVjdoaUpCY05rN0pJSXhfYXVKMDRoMS16MnVpVFB2aFFmcDJWQ2sxTU15MTladmNFZnhmd0dudk5FVkJDQ0toMEVNQ1FXWmpNV0RCWlhHcW1iYmxPNWZBNnIwaTk3ZEpzU1IwNW1TdnpkWVY0eHFkYWlHcm96VEkxREUzeUpmajJwaGdFbHc5bGprNmh4QllXcGZXajdyRkdpeFlfQ3Bqcmo3OUhmdWo3Ulc2QTV6dERkMFE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/verastem-says-vs-7375-trial-204406965.html", "source_name": "MT Newswires", "published_at": "2026-06-23T20:44:06+00:00", "published_display": "23 Jun 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem posts VS-7375 data, reports anti-tumor activity at 400\u2013900 mg QD and 93% CA19-9 drops in mPDAC", "summary": "Verastem reported positive preliminary data for its drug VS-7375, showing anti-tumor activity at doses of 400\u2013900 mg once daily and significant biomarker responses in metastatic pancreatic ductal adenocarcinoma (mPDAC). Key findings include ongoing dose escalation, anti-tumor act", "url": "https://www.tradingview.com/news/tradingview:76de15f6e44cd:0-verastem-posts-vs-7375-data-reports-anti-tumor-activity-at-400-900-mg-qd-and-93-ca19-9-drops-in-mpdac/", "source_name": "TradingView", "published_at": "2026-06-23T20:09:27", "published_display": "23 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem says VS-7375 hit pancreatic, colon and lung tumors", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMHd4QU5HNFpld284N25OSTNtT3hJcEhvOHBqSi1WMzVENHkxcDROVUtTYi1yN3NOYl9ickRwdW44STU2aVdsdDZpSkRMZloxQXpjS0VpSm50bVc0TkJQWHdhbEhyVnpESi1wNHl4UVNodEIzLUh0bmJZRUl1YzNER1Izc2Y3QUhScEsweWVobHhKa0dmV0R1dWg5YUxEelJocjZ6aThMVkhRemFhU3A4N0pEQjJoMG12dEsxdnl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem stock falls despite early cancer drug trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMDFzNHlCX3R4bXBHeTA4aHppZkE5T2RhbTAyVkZlczlZSmlROUp3dWh3U29NazJmX1JZUWh3WTN4ZzdIQ1RmUXcycGpjaTZGMmJFdWNPRXBadFdkRUVTT2RudDdhSUJFM192cWRmZVZvZTBwLTY1NzJLak9KRVVwSkNYeXl5N3k5R05oMG9oRzk0NlFlS1N2VDZ2Ym9faFh6T1lMWmlHb2ZCMzRpUTMzQ0t5NkJhdnYxM1pn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (NASDAQ: VSTM) insider sale notice \u2014 20,871 shares proposed", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOUFBQM094M3ZVcEh3WkJXTHFxSTZzT2JTNTFFVVZrR2pTTEw4NnZrdm1hRHdsc0hPX2xfQ2oxR3ZEV0JSTVFqNWxfRzY2U28zc3dDR3ZoelNjSlAxZ1EzVm54V1lXSWZzQTgtV1BJeUFSTTJzaVdiZUoxRTUySTU3ZktDTXRyTHY2bGJOQk1FUXdmTnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Business Wire", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Verastem, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNTk45QzJvdmtiRHByXzd0VTNJMXFlN3FCeE1FSVZmaFcxY2RuNm5KNG9wcjBPTW9uNWgzQmZxb3dERWUyUzdYZmszVm9XT0RVNTAtSFc4M1RxSjVlV2NjR01XbHA2RGVXYWRWZ1Bac2pzR2RUNjlOYlJQQ1JkUjF4bWU5emp5ZllMYk00TmxHbW9QY3M?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNQVFveUFVbEFta3pzVFdmS3dXajdZZ1ppYndTaDl2TS1pVFViOUw0dE1jRl9KWEZqX3FiT0dLMUhBTWJPdndRRDJJOFdVSURGcXhpWDB0X2pYV0t1OTZZUm5nVDR2Vk94cVBQbEppTzhuZnhBdnJ5S3B2dVltUlU2NV93QXQ3V3FiT2VBRU5EZy1PaWM?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts Think", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNSW5BdlpVVXd1cDF4WGVkYTZzVjF6MmxHNWRtcXktMldRdHhYb3JzVVMxMTFDLVZUZ1lKRk1sM0RoRlRxM00xV2FrMEhKNUl6czl5RXk0eFZwaFljUURzbHNjaktJWXN0TU1kaVJmV0FIMExQWWpqbXBkaWUzU0VpT1BreHFfeVFLQXJWUzFFT19aQVpiSmpQTV9B?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Q4 Revenue Reaches US$17.5 Million Yet Heavy Losses Reinforce Bearish Views", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxPU2ZsN0o4bVI5dnd3b0V0V01RRDd3LURtMEpiTWNtVzhTcXRTUTVmTGwta0RVQm1yajk3cHk0Z24xQ056UDVoSXpzVTZlT0ZfOG9sb1llVnpoQmt2TFVaLWo1YTRwVUU5eGc2SU42eGMxR0NWU0dfanBlZ1QtRUdEczFxNkdJSl8xQ2U5YnVsa19vMm1tdjNpNzdOWi0tY2FtbFAxODZDM29aeWFBalF5Q3c5X1hEaWEzTmFtQUJYZUxhVWZKSXZFTUtMQ2JrYVpyckVhUmFVZE53MWx3UWt3LTNxeUxNN2d2dm1hQi1MZw?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQT2V0TV94Z091d1U4eHhTMS1VNjNQUVVRY2tjeEF4QWc3Uzl4Zy1sSGlxdlRUZTBjWFZWRVVmSmg2VExpX0k0Wm1fQndLR1preW5aSmRfNzJpcy11RUJObm5QRTdkb2lLeVJyaTlTUXdWRVRMX2tMRWMxa1B4anlvc1Z0UGlaTXE0UlAtUk1LTlk4U2R1Z3Y0OVFn?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPWDlaVlFMX2V1WVFsU2FZYmQwVExESnBaR1U4SUNPZGJ3ZFlLdHNIY0hYWkFzcmdVZXlxdldtbk14SDZzbHNrX3AzT3hHcnd2eXRFdTlXOC1STFlNTHpIck1HM0xJMFVUV3pOM1FfbWROdDF5Tk53WXZJUV9zT3VDb1pSd0hGeE9ZaXBqZTVianZDRzlXY1g1MEtQYmFJQk4zcFVtVUo0VWE4MWVWd19kUHFxakZiWm9IXzlZTDNmWTZFOTBIaXRz?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Verastem (VSTM) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb0I0VkFIVm5TWnpsY1BLRUtOMTltU2NoaGRoM05WZGtSLVpLMGhjMUJickR3UERNeHBnQTJjdWUwcHhVYW15dlZNaldaRzRxU2VPOE9yZENVQVZMbjl2d1JBWloyVHdrOTR5SzFsMi1mcmI3b3pNSGM2eHZuSld0Zg?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Verastem Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-26T08:00:00+00:00", "published_display": "26 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 55, "sentiment_summary": {"positive": 13, "negative": 11, "neutral": 31, "score": 52, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.2, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 4.95, "count": 9}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 5.53, "latest_week": "2026-07-10", "one_week_move": 22.9, "four_week_move": 34.9, "twelve_week_move": -16.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.055695, "market_dynamics_buy_signal": false, "relative_strength": -32.258473, "fair_value_gap": -19.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.7809, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+22.9% over one week, +34.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 8}, {"label": "simplywall.st", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "Insider Monkey", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 9}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+22.9% over one week, +34.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)"}], "updated_at": "2026-07-16T09:44:09.306946+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}